key: cord-0817066-2gd5v1zj
authors: Lartey, Nathaniel L.; Valle-Reyes, Salvador; Vargas-Robles, Hilda; Jiménez-Camacho, Karina E.; Guerrero-Fonseca, Idaira M.; Castellanos-Martínez, Ramón; Montoya-García, Armando; García-Cordero, Julio; Cedillo-Barrón, Leticia; Nava, Porfirio; Filisola-Villaseñor, Jessica G.; Roa-Velázquez, Daniela; Zavala-Vargas, Dan I; Morales-Ríos, Edgar; Salinas-Lara, Citlaltepetl; Vadillo, Eduardo; Schnoor, Michael
title: ADAM17 inhibition prevents neutrophilia and lung injury in a mouse model of Covid-19
date: 2021-04-11
journal: bioRxiv
DOI: 10.1101/2021.04.10.439288
sha: 2744b798c5061b32bde36acaa3ddd4909e264cc2
doc_id: 817066
cord_uid: 2gd5v1zj

Severe coronavirus disease 2019 (Covid-19) is characterized by lung injury, cytokine storm and increased neutrophil-to-lymphocyte ratio (NLR). Current therapies focus on reducing viral replication and inflammatory responses, but no specific treatment exists to prevent the development of severe Covid-19 in infected individuals. Angiotensin-converting enzyme-2 ACE-2) is the receptor for SARS-CoV-2, the virus causing Covid-19, but it is also critical for maintaining the correct functionality of lung epithelium and endothelium. Coronaviruses induce activation of a disintegrin and metalloprotease 17 (ADAM17) and shedding of ACE-2 from the cell surface resulting in exacerbated inflammatory responses. Thus, we hypothesized that ADAM17 inhibition ameliorates Covid-19-related lung inflammation. We employed a pre-clinical mouse model using intra-tracheal instillation of a combination of polyinosinic:polycytidylic acid (poly-I:C) and the receptor-binding domain of the SARS-CoV-2 spike protein (RBD-S) to mimic lung damage associated with Covid-19. Histological analysis of inflamed mice confirmed the expected signs of lung injury including edema, fibrosis, vascular congestion and leukocyte infiltration. Moreover, inflamed mice also showed an increased NLR as observed in critically ill Covid-19 patients. Administration of the ADAM17 inhibitors apratastat and TMI-1 significantly improved lung histology and prevented leukocyte infiltration. Reduced leukocyte recruitment could be explained by reduced production of pro-inflammatory cytokines and lower levels of the endothelial adhesion molecules ICAM-1 and VCAM-1. Additionally, the NLR was significantly reduced by ADAM17 inhibition. Thus, we propose inhibition of ADAM17 as a novel promising treatment strategy in SARS-CoV-2-infected individuals to prevent the progression towards severe Covid-19.

Massive neutrophil infiltration is a key feature of Covid19-associated lung injury (26, 27) . Because 255 the histology indicated reduced leukocyte presence in lungs after ADAM17 inhibition, we 256 quantified leukocyte populations by flow cytometry. As expected, the number of neutrophils was 257 strongly increased after instillation of poly-I:C/RBD-S, and both apratastat and TMI-1 258 significantly reduced the number of neutrophils in the lungs (Fig. 3A) . Also, the number of lung Pro-inflammatory cytokines, especially TNF-α, are known to activate endothelial cells that 299 respond by expressing adhesion molecules for leukocytes to enable their extravasation (30).

Accordingly, poly I:C/RBD-S induced strong expression of ICAM-1 (Fig. 5F ) and VCAM-1 ( Fig.   301 5G) in lungs; and both apratastat and TMI-1 reversed this overexpression back to control levels.

This reduction in endothelial adhesion molecules likely explains the reduced leukocyte recruitment 303 to the lungs after ADAM17 inhibition.

Intranasal administration of ADAM17 inhibitors also prevents excessive leukocyte recruitment to 306 the lungs in response to poly I:C/RBD-S 307 All data described above were obtained after intraperitoneal administration of the ADAM17 308 inhibitors. As this is not a desirable route of applying drugs in human patients, we wanted to know 309 whether local application of apratastat via the intranasal route would show similar effects. Moreover, surface protein expression of ICAM-1 on endothelial cells was also significantly 320 reduced after intranasal apratastat administration (Fig. 7 ). Together these data show that intranasal administration (e.g. inhalation) is also an efficient route of application of apratastat to combat 322 Covid-19-associated lung inflammation. only used relatively young mice (8-10 weeks). It will be interesting to see whether older or obese 362 animals will develop the more severe disease because if so, this model will also be appropriate to 363 study the molecular differences in high-risk groups.

ACE2 is not just the receptor for SARS-CoV and SARS-CoV-2 (7, 34), but it is also a critical 365 enzyme regulating the production of angiotensinogenic peptides, inflammation, and vascular and 366 epithelial permeability (8) as TNF-α-converting enzyme (TACE), is responsible for producing the active form of TNF-α (11).

We showed that TNF-α production is indeed significantly reduced after ADAM17 inhibition in 

Neutrophil Recruitment: From Model Systems 598 to Tissue-Specific Patterns

Leukocyte trafficking to the lungs and beyond: lessons from influenza 601 for COVID-19

Metalloproteinase inhibitors for the disintegrin-604 like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and 605 phorbol ester-inducible shedding of cell surface molecules

Drug insight: tumor necrosis 608 factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis

Drug evaluation: apratastat

Pharmacokinetic-pharmacodynamic modeling of apratastat: a population-based approach